Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
NCT ID: NCT01450306
Last Updated: 2024-03-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2010-07-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
NCT00591825
The Warmth, Anticipation, Sensation, Aversion, and Body-part Imaging Study
NCT04653064
Pilot Trial of Hypnosis and Enhanced Communication In Patients Undergoing MRI
NCT04520100
Brain Imaging Changes in Fear and Anxiety
NCT00047853
Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia
NCT00302978
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-cycloserine plus exposure therapy
Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
D-cycloserine
50 mg d-cycloserine, oral, 1 dose
Exposure therapy
Single session graded in vivo exposure therapy, 60-180 minutes
Placebo plus exposure therapy
Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
Exposure therapy
Single session graded in vivo exposure therapy, 60-180 minutes
Placebo
Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-cycloserine
50 mg d-cycloserine, oral, 1 dose
Exposure therapy
Single session graded in vivo exposure therapy, 60-180 minutes
Placebo
Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Recent substance abuse or suicidality
* Previous receipt of study treatments
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hartford Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Tolin, PhD
Role: PRINCIPAL_INVESTIGATOR
Hartford Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Living/Hartford Hospital
Hartford, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nave AM, Tolin DF, Stevens MC. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry. 2012 Sep;73(9):1179-86. doi: 10.4088/JCP.11m07564.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAVE003220HU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.